Loading the procedure…
Loading the procedure…
Medicare volume, surgeons, state markets and device makers
Deep brain and vagus nerve stimulator implants. Main billing specialty: neurosurgery.
Medicare fee-for-service DBS & VNS cases in the 31 states summed: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 17% on average (103 state-years, 2020–2024): small markets swing, so treat it as rough.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 18 | 1,061−2.2%/yr | −2.2%/yr | 0.30.9× | 0% | 1,120 in 2030+0.8%/yr |
| Texas | 18 | 941−0.6%/yr | −0.6%/yr | 0.41.3× | 2% | 1,460 in 2030+7.6%/yr |
| Florida | 13 | 844+0.5%/yr | +0.5%/yr | 0.41.1× | 2% | 1,550 in 2030+11%/yr |
| Pennsylvania | 4 | 485−4.3%/yr | −4.3%/yr | 0.31.0× | 0% | 620 in 2030+4.1%/yr |
| New York | 8 | 452−3.8%/yr | −3.8%/yr | 0.20.7× | 0% | 480 in 2030+0.9%/yr |
| Ohio | 9 | 430−6.8%/yr | −6.8%/yr | 0.41.1× | 0% | 580 in 2030+5.2%/yr |
| Washington | 6 | 357−1.8%/yr | −1.8%/yr | 0.51.4× | 0% | 290 in 2030−3.1%/yr |
| Minnesota | 3 | 324−2.1%/yr | −2.1%/yr | 0.72.1× | 0% | 460 in 2030+6.1%/yr |
| Arizona | 4 | 305−10%/yr | −10%/yr | 0.41.2× | 0% | 540 in 2030+9.8%/yr |
| Kansas | 3 | 294+5.3%/yr | +5.3%/yr | 0.72.2× | 0% | 570 in 2030+12%/yr |
| Illinois | 4 | 294−8.4%/yr | −8.4%/yr | 0.20.6× | 0% | 330 in 2030+2.2%/yr |
| North Carolina | 8 | 293−8.9%/yr | −8.9%/yr | 0.30.9× | 0% | 440 in 2030+7.1%/yr |
| Colorado | 5 | 282−2.4%/yr | −2.4%/yr | 0.61.7× | 14% | 540 in 2030+12%/yr |
| Missouri | 3 | 276−9.1%/yr | −9.1%/yr | 0.41.3× | 0% | 290 in 2030+0.5%/yr |
| Virginia | 5 | 275−0.4%/yr | −0.4%/yr | 0.30.8× | 0% | 420 in 2030+7.4%/yr |
| Tennessee | 4 | 252+1%/yr | +1%/yr | 0.31.1× | 0% | 270 in 2030+1.2%/yr |
| Michigan | 2 | 246−8.8%/yr | −8.8%/yr | 0.30.8× | 0% | 130 in 2030−10%/yr |
| Massachusetts | 6 | 233−7.5%/yr | −7.5%/yr | 0.20.7× | 0% | 270 in 2030+2.6%/yr |
| Georgia | 3 | 211+0.2%/yr | +0.2%/yr | 0.20.7× | 0% | 230 in 2030+1.1%/yr |
| New Jersey | 4 | 206+7.7%/yr | +7.7%/yr | 0.20.6× | 0% | 280 in 2030+5.4%/yr |
| Kentucky | 5 | 203−3.5%/yr | −3.5%/yr | 0.41.3× | 0% | 330 in 2030+8.4%/yr |
| Alabama | 4 | 187−6.5%/yr | −6.5%/yr | 0.41.2× | 0% | 190 in 2030+0.5%/yr |
| Indiana | 2 | 163−10%/yr | −10%/yr | 0.20.7× | 0% | 320 in 2030+12%/yr |
| Wisconsin | 3 | 158−3.1%/yr | −3.1%/yr | 0.30.8× | 0% | 140 in 2030−2.5%/yr |
| Oklahoma | 3 | 152+4.2%/yr | +4.2%/yr | 0.30.9× | 0% | 150 in 2030−0.1%/yr |
| South Carolina | 2 | 151−3.2%/yr | −3.2%/yr | 0.20.6× | 0% | 260 in 2030+9.8%/yr |
| Louisiana | 2 | 151−6.2%/yr | −6.2%/yr | 0.41.1× | 0% | 1,100 in 2030+39%/yr |
| Montana | 1 | 133−4.9%/yr | −4.9%/yr | 0.72.1× | 0% | 140 in 2030+1.3%/yr |
| Oregon | 2 | 124−13%/yr | −13%/yr | 0.30.9× | 0% | 140 in 2030+1.9%/yr |
| Iowa | 1 | 123−7.4%/yr | −7.4%/yr | 0.30.8× | 0% | 200 in 2030+8.6%/yr |
| Maryland | 1 | 111−4.1%/yr | −4.1%/yr | 0.10.4× | 0% | 120 in 2030+1.8%/yr |
Professional codes (what the surgeon bills): CPT 61863, 61867, 61885, 61886, 64568; the hospital bills MS-DRG 040, 041, 042.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed, summed over the states listed: states MedaRep covers where the procedure tops 100 Medicare cases a year. All Medicare adds Medicare Advantage patients at each state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. How the numbers are made · Data sources
In the last 10 years FDA made 575 decisions (510(k) clearances, De Novo grants, PMA approvals and supplements) under this category’s product codes, held by 5 companies. The most active:
| Company | Decisions, 10 years |
|---|---|
| Medtronic | 266 |
| Abbott | 116 |
| Boston Scientific | 94 |
| Neuropace | 53 |
| Livanova | 46 |
Product codes: LYJ (stimulator, autonomic nerve, implanted for epilepsy), MHY (stimulator, electrical, implanted, for parkinsonian tremor), NHL (stimulator, electrical, implanted, for parkinsonian symptoms), PFN (implanted brain stimulator for epilepsy). A company whose devices for this procedure are filed under other codes is not counted, and a PMA supplement counts as a decision of its own. Applicants are rolled up to their parent company.
The competitive landscape: each company scored on innovation pace, recall and report signals, commercial momentum and financial capacity.
The 10 busiest do 79% of the cases CMS names in California; 11 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Procedure | Surgeons | Medicare FFS | Growth since 2019 | Forecast |
|---|---|---|---|---|
| Aneurysm & intracranial embolization | 398 | 14,006+13%/yr | +13%/yr | 25,900 in 2030+11%/yr |
| Stroke thrombectomy | 446 | 12,543+1.7%/yr | +1.7%/yr | 14,600 in 2030+2.5%/yr |
| CSF shunts | 56 | 5,163−4.8%/yr | −4.8%/yr | 6,290 in 2030+3.3%/yr |
Every procedure · Markets by state · Device companies · Compare two states
In 2025, 10 companies reported engagement with surgeons in the covered states worth $5.9M in consulting, speaking, meals and travel tied to these products, about $38K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 56 clearances and approvals in the category, 2 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the state rankings. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.